Hib-DTP-hepatitis B vaccine (Easyfive-TT) - Panacea Biotec

Drug Profile

Hib-DTP-hepatitis B vaccine (Easyfive-TT) - Panacea Biotec

Alternative Names: DTwP-HepB-Hib vaccine - Panacea Biotec; Easy-five; Easyfive-TT; My Five; Pentavalent vaccine - Panacea Biotec

Latest Information Update: 14 Mar 2016

Price : $50

At a glance

  • Originator Panacea Biotec
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 14 Mar 2016 Phase-III development is ongoing in Egypt
  • 14 Mar 2016 No recent reports on development identified - Phase-III for Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus infections (Prevention) in Thailand and Chile (IM)
  • 31 Dec 2013 Launched for Diphtheria, Tetanus, Pertussis, Haemophilus infections and Hepatitis B (prevention) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top